Senses Disorder TRIZ Cases

Nanocarriers encapsulate jasmonate compounds, protecting them from esterase degradation in the bloodstream and enabling targeted delivery to cancer cells.

Specific CDR mutations in an antigen binding protein boost binding affinity, addressing limited therapeutic effects of existing PNH treatments.

Click chemistry forms triazole-linked polymer conjugates that control drug release while maximizing loading capacity.

Polymeric quaternary ammonium compounds with hyaluronic acid reduce lens uptake while maintaining antimicrobial efficacy against Candida.

Humanized anti-Ang2 antibodies induce Tie2 activation, resolving the trade-off between enhanced anti-cancer efficacy and insufficient half-life.

Emulsifiers transform hydrophobic cannabis oil into water-soluble droplets, resolving slow and variable absorption in edible products.

Differentiating pluripotent stem cells into retinal pigment epithelium via embryoid body formation addresses contamination risks in donor-derived therapies.

A nasal dispensing device uses a conically shaped internal bottom to deliver mometasone and olopatadine.

Visible light photoinitiators crosslink ocular tissues to strengthen corneas, eliminating epithelial removal pain and UV damage risks.

XTEN fusion proteins resolve lability and aggregation issues by extending circulation half-life and maintaining therapeutic activity.

Sodium iodine catalyzes hydrogen peroxide decomposition into water and oxygen within a riboflavin-based ophthalmic composition.

An erosion matrix with rate-controlling agents provides sustained release of fumaric acid esters, reducing gastrointestinal side effects.

Variant Fc-regions with specific amino acid mutations alter binding affinity to extend systemic retention times.

Micelle formation overcomes poor absorption in premature infants while eliminating toxic preservatives like chlorobutanol.

Selective inhibition of the Ape1/Ref-1 redox function by E3330 resolves the contradiction between anti-angiogenic activity and genomic stability.

Targeted iRNA agents silence HIF-1α expression to inhibit neovascularization in age-related macular degeneration.

Fused pyridine ring compounds inhibit Bruton's tyrosine kinase selectively, avoiding Src-family kinase inhibition to reduce adverse effects.

Reduced and highly oxidized polysaccharides form non-toxic hydrogels that encapsulate therapeutic agents and liposomes.

Covalent bonding to a cysteine residue enables irreversible Bruton's tyrosine kinase inhibition, resolving selectivity challenges in treating B-cell disorders.

An eye drop formulation reduces sSema4D concentration to control macular edema, avoiding intravitreal injection risks.

Humanized monoclonal antibodies bind RAGE C-domains to block amyloid-beta interactions, reducing plaque formation and improving cerebral blood flow.

N,N-disubstituted aminoalkylbiphenyl compounds block PGD2 binding to the DP2 receptor, resolving inflammation in asthma and rhinitis.

Anti-RhoB antibodies inhibit abnormal neovascularization and resolve avascular pathology in diabetic retinopathy models.

Benzoheterocyclic compounds inhibit protein kinases, reducing toxicity while maintaining therapeutic efficacy against cancers.

Cultures pluripotent stem cells in defined media using specific signal pathway modulators to form uniform retinal tissue aggregates.

Modified paromomycin structures increase protein expression in mammalian cells while reducing toxicity and antimicrobial activity.

Pyridine derivatives inhibit TBK1 and IKKe kinases, addressing the lack of effective inhibitors for cancer and inflammatory diseases.

Sustained release LEDGF peptide formulations bypass frequent intravitreal injections, maintaining retinal drug levels and improving patient compliance.

Segmented shark IgNAR variable regions neutralize cytokines with enhanced stability.

Fermented Lactobacillus paracasei supernatant acts as a postbiotic eyedrop formulation to deliver anti-inflammatory effects.

Natural pigment composition replaces atropine side effects by suppressing axial elongation through EGR-1 gene enhancement in functional foods.

Dihydrothienopyrimidine compounds address broad therapeutic potential gaps across respiratory, gastrointestinal, and nervous system conditions.

Thermoresponsive polymer transitions from liquid to gel in the tear duct, replacing invasive punctal plugs with a minimally invasive treatment.

A tricyclic compound acts as a GPR40 receptor agonist to modulate insulin secretion from pancreatic beta cells.

Chitin-based saccharides promote olfactory receptor neuron maturation via intranasal topical application.

A polymeric intraocular lens releases therapeutic agents through controlled diffusion mechanisms.

Antagonists block G-CSF signaling to control inflammation without neutrophil depletion.

Humanized anti-OAcGD2 antibodies target O-acetylated GD2 gangliosides while avoiding nerve cell binding to eliminate neurotoxicity.

A single-stranded polynucleotide links sense and antisense strands via a phenyl group-containing linker to form a stable phosphodiester structure.

Intraocular fluid dissolves the gas to drive sustained release, preventing protein deactivation during processing.

Anti-Sema3A antibodies neutralize Sema3A protein to redirect angiogenesis toward ischemic regions, reducing pathological neovascularization.

Aryl dihydropyridinone compounds inhibit monoacylglycerol acyltransferase 2, addressing inadequate management of obesity and type II diabetes.

Selective bicyclic compounds target specific Rho-associated kinase isoforms for precise therapeutic action.

Gly-O-iPr suppresses sensory discomfort in non-keratinized tissues without irritancy or toxicity.

Imidazolothiazole compounds achieve selective kinase inhibition by tailoring molecular substituents, reducing off-target effects while treating disease.